333
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Associations of Medication Regimen Complexity with COPD Medication Adherence and Control

, , &
Pages 2385-2392 | Published online: 19 Aug 2021
 

Abstract

Introduction

Medication adherence is often low among people with chronic obstructive pulmonary disease (COPD) and medication regimen complexity may be a contributing factor. In this study, we sought to examine the role of medication regimen complexity in COPD medication adherence among patients with multimorbidity.

Methods

We performed cross-sectional analysis of data on COPD patients in primary care and pulmonary practices in New York City and Chicago (n=400). Regimen complexity was represented by the medication regimen complexity index (MRCI) and simple medication count. Adherence was measured by self-report and inhaler dose counts. Disease control measures included the COPD severity score (COPDSS) and the Medical Research Council (MRC) severity index.

Results

Mean age of study participants was 69 years, 66% had MRC grades 4 or 5, and 45% had low medication adherence. MRCI scores did not differ significantly between those with and without adequate medication adherence. Patients with higher MRCI scores were more likely to have severe COPD (OR 5.00, 95% CI 1.46–17.1, p=0.01) and dyspnea grades 3 or 4 (OR 2.27, 95% CI 1.03–5.03, p=0.04). Significant associations of medication count with COPD severity were also observed.

Discussion

These findings demonstrate that among patients with COPD and comorbid hypertension and diabetes, higher medication regimen complexity is associated with worse COPD control but not with COPD medication adherence.

Ethics Statement

This study was conducted in accordance with the Declaration of Helsinki.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure

Dr. Wolf reports grants from Amgen, Eli Lilly, AbbVie, and Lundbeck, personal fees from Sanofi and Luton UK, and grants and personal fees from Pfizer and Merck, Sharpe & Dohme. Dr. Wisnivesky reports grants and personal fees from Sanofi, personal fees from Banook and Atea, and grants from Arnold. The authors report no other conflicts of interest in this work.

Additional information

Funding

National Heart Lung and Blood Institute, R01 HL126508